Facilitating cancer progression via activation of ERα and PI3K/AKT/NF‐κB signaling; inducing tamoxifen resistance by activating PI3K/Akt/mTOR signaling; enhancing growth and cell‐cycle progression through SRC and PKC activation. This evidence concerns the gene PRRT2 and cancer.